Protection against Covid-19 by BNT162b2 Booster across Age Groups

BACKGROUND: After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons 60 years of age or older, the booster campaign in Israel was gradually expanded to persons in younger age groups who had received a second...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-On, Yinon M., Goldberg, Yair, Mandel, Micha, Bodenheimer, Omri, Freedman, Laurence, Alroy-Preis, Sharon, Ash, Nachman, Huppert, Amit, Milo, Ron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728796/
https://www.ncbi.nlm.nih.gov/pubmed/34879188
http://dx.doi.org/10.1056/NEJMoa2115926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728796/
https://www.ncbi.nlm.nih.gov/pubmed/34879188
http://dx.doi.org/10.1056/NEJMoa2115926

Ejemplares similares